Acepre, LLC
Columbia, SC
- UEI
- NX6XWKC8C4B5
- CAGE
- 7SYL2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- SAM.gov registration date
- Physical address
- 6439 Garners Ferry Rd, Columbia, SC 29209, USA
- Website
- aceprehealth.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Acepre, LLC is a Columbia, South Carolina-based limited liability company registered in the System for Award Management (SAM.gov) since January 2017, with a registration valid through October 2025. As a for-profit organization, the company appears to be focused on biomedical research and drug development, specifically targeting complex medical conditions through innovative therapeutic approaches. The company seems to collaborate closely with academic research institutions, particularly the University of South Carolina, to develop potential treatments for various diseases.
Through its federal grant awards, Acepre, LLC has been actively pursuing research and development of novel therapeutic compounds across multiple medical domains, with a particular emphasis on neurodegenerative diseases, cardiovascular conditions, and critical care treatments. The company has received multiple Small Business Technology Transfer (STTR) Phase I grants from prestigious National Institutes of Health (NIH) institutes, including the National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Center for Complementary and Integrative Health, and National Cancer Institute. Their research focuses on developing innovative treatments such as a brain-targeted delivery system for N-acetylcysteine for Alzheimer's disease, using emodin as a potential therapy for calcific aortic valve disease and alcoholic cardiomyopathy, exploring nanoenzyme approaches for AD treatment, investigating compounds to treat bacterial sepsis, and developing polymer-metal nanocomplexes for ovarian cancer treatment. Each project demonstrates a sophisticated approach to drug development, involving detailed preclinical studies, toxicity assessments, and potential pathways to FDA investigational new drug (IND) applications.
Quick answers
Is Acepre, LLC registered in SAM.gov?
Yes. Acepre, LLC's SAM.gov registration is active through July 20, 2027.
What is Acepre, LLC's CAGE code?
Acepre, LLC's CAGE code is 7SYL2, and its Unique Entity ID (UEI) is NX6XWKC8C4B5.
What is Acepre, LLC's most recent federal award?
Acepre, LLC's most recent federal grant award is Develop natural compound emodin as a novel therapy for calcific aortic valve disease (R41HL172481), from National Heart Lung and Blood Institute (NIH), on September 17, 2024.
On GovTribe
See Acepre, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors